吗氯贝胺与阿米替林对照治疗抑郁症的系统评价

Systematic Review on Moclobemide vs Amitriptyline for Treating Depression

目的比较吗氯贝胺与阿米替林治疗抑郁症的临床疗效及不良反应发生情况。方法检索1994年至2014年国内关于吗氯贝胺与阿米替林治疗抑郁症的对照研究文献，应用系统评价方法对查阅到8篇随机对照研究进行评价。结果吗氯贝胺与阿米替林的临床疗效比较，差异无显著性[P〉0．05，OR=1．28，95％CI（0．79～2．08）]，吗氯贝胺组不良反应发生率为9．76％，明显低于阿米替林组的23．62％（P〈0．05），吗氯贝胺组震颤、口干、心悸、嗜睡、视物模糊、便秘、心动过速、排尿困难发生率均明显低于阿米替林组（χ2=4．99，P〈0．05），但失眠、激越的发生率明显高于阿米替林组（χ2=6．68，P〈0．01）。其他不良反应发生率比较，差异无统计学意义（P〉0．05）。结论吗氯贝胺与阿米替林治疗抑郁症的疗效相当，但前者不良反应较少。

Objective To compare the clinical efficacy and adverse reactions of moclobemide vs amitriptyline in treating depres- sion. Methods Totally 8 randomized controlled trails （RCTs） literatures of moclobemide vs amitriptyline in treating depression were re- trieved from 1994 to 2014 and evaluated by systematic evaluation method. Results The clinical efficacy between moclobemide and amitriptyline had no significant difference[ P 〉 0. 05, OR = 1.28,95% CI（0. 79 - 2.08）]. the incidences of ADR was 9.76% in mo- clobemide group,which was significantly lower than 23.62% in amitriptyline group（P 〈 0.05）.The incidences of adverse reactions such as tremor, dry mouth, palpitation, drowsiness, blurred vision, constipation, tachycardia, dysuria in moclobemide group were significantly lower than that of amitriptyline group（χ2 =4. 99, P 〈 0. 05）,but insomnia,agitation in moclobemide group were significantly higher than that of the amitriptyline group（χ2 =6.68, P 〈 0.01）. There was no significant difference of others adverse events between the two groups （P 〉 0. 05 ）. Conclusion Moclobemide and amitriptyline have the same effect for treating depression, but the incidence of mo- clobemide is lower.